Out of the shadows: Mental health in the Asia Pacific region
Published in eyeforpharma February 2018 by Marc Yates
Mental health has been a peripheral issue in emerging markets for a long time, despite the severe impact it can have, not only on those directly affected but also on families, carers, social cohesion, and economic development. Fortunately, mental health is starting to get more attention, but there is still a widespread tendency to stigmatise and discriminate against people suffering with a mental illness. They are often considered as dangerous and aggressive which in turn increases the social distance.
Is there an opportunity for pharma to do more? In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia where problems arising from ill mental health are the second largest contributor to years lost to disability (YL:D).
Heather Desmet appointed new Head of Living With
We are delighted to welcome Heather Desmet as Head of Living With at the company’s London headquarters.
Heather joins us from an gency specialising in large scale syndicated research projects within the Southern African healthcare sector. Heather brings with her more than 10 years of experience in a wide variety of qualitative and quantitative methodologies, utilised across the private and public healthcare sectors. She has extensive experience in market understanding, communications, patient and provider positioning research and project management.
The Difficulties of Living with Depression Don't End with the Illness Itself
Mary Assimakopoulos, eyeforpharma 15th August 2013
This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness. On a flight back from the US a few weeks ago I watched the film Side Effects, a recently-released psychological thriller which takes a swipe at the medical profession, big pharma and the treatment of mental health. Manhattan psychiatrist Dr Jonathan Banks’ (Jude Law) world is turned upside down when a patient he treats with a new anti-depressive apparently kills her husband because of the side effects of her medication. Whilst an extreme dramatisation, the film does highlight some of the challenges the healthcare profession faces when treating depression. There is no one ideal treatment or solution - patients typically cycle through a range of prescriptive medicines and therapy until they find a treatment programme that works for them.In our market research study into depression, conducted amongst 2,000 patients in the USA, Germany and the UK, we undertook a latent class analysis which identified four patient segments. We titled these patient types Apprehensive Annie, Positive Paul, Get-on-with-it Greg and Resigned Rachel. Apprehensive Annie and Resigned Rachel formed the two largest patient segments – comprising 38% and 30% of the…